CDX2 and colorectal adenocarcinoma: In another study, Raspollini proved that immunostaining with antibodies anti-CDX-2, CK7, CK20, and CEA can be used to differentiate a primary bladder adenocarcinoma from a secondary colorectal adenocarcinoma [8].